Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.
Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Kraut J, et al. Among authors: abernethy ap. J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. J Oncol Pract. 2019. PMID: 30883256 No abstract available.
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
O'Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. O'Connor JM, et al. Among authors: abernethy ap. JAMA Oncol. 2018 Aug 1;4(8):e180798. doi: 10.1001/jamaoncol.2018.0798. Epub 2018 Aug 9. JAMA Oncol. 2018. PMID: 29800974 Free PMC article.
Use of Electronic Health Record Data for Quality Reporting.
Abernethy AP, Gippetti J, Parulkar R, Revol C. Abernethy AP, et al. J Oncol Pract. 2017 Aug;13(8):530-534. doi: 10.1200/JOP.2017.024224. Epub 2017 Jul 26. J Oncol Pract. 2017. PMID: 28745935 No abstract available.
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA. Singal G, et al. Among authors: abernethy ap. JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241. JAMA. 2019. PMID: 30964529 Free PMC article.
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister P, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP. Khozin S, et al. Among authors: abernethy ap. Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27. Oncologist. 2019. PMID: 30591549 Free PMC article.
436 results